Literature DB >> 17418007

Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra).

I Koné-Paut, K Retornaz, J M Garnier, B Bader-Meunier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418007

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  7 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 3.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

Review 4.  [The importance of biologicals in the treatment of SoJIA].

Authors:  G Dückers; T Niehues
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

5.  Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.

Authors:  Linda Rossi-Semerano; Bruno Fautrel; Daniel Wendling; Eric Hachulla; Caroline Galeotti; Luca Semerano; Isabelle Touitou; Isabelle Koné-Paut
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

6.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06

Review 7.  Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Authors:  Ioannis D Xynos; Maria G Tektonidou; Dimitrios Pikazis; Nikolaos V Sipsas
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.